A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a noninvasive blood test to predict lymph node metastasis in early lung adenocarcinoma (LUAD). The model accurately identifies patients with metastasis, aiding treatment decisions.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Lung adenocarcinoma (LUAD) is a prevalent lung cancer subtype.
- Accurate prediction of lymph node metastasis is critical for early LUAD treatment and prognosis.
Purpose Of The Study
- To develop a noninvasive method for predicting lymph node metastasis in early-stage LUAD.
- To identify novel RNA biomarkers in serum for metastasis risk assessment.
Main Methods
- Transcriptome sequencing of T1 LUAD tissues to identify metastasis-associated RNA molecules.
- Validation of RNA expression in serum using real-time quantitative PCR.
- Development and validation of a predictive model using training (96 patients) and validation (158 patients) cohorts.
Main Results
- Identified 11 RNA molecules (e.g., miR-412, ID1, MMP13) associated with lymph node metastasis in T1 LUAD tissues.
- Developed a serum-based predictive model using nine RNA molecules, excluding FOXC1 and COL11A1.
- Achieved high accuracy with an AUC of 0.89 in the training set and 0.91 in the validation set.
Conclusions
- Established a novel, noninvasive risk prediction model for lymph node metastasis in T1 LUAD using serum samples.
- The model enables accurate identification of patients with positive lymph node metastasis.
- This approach can guide treatment decisions and improve patient outcomes for early LUAD.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.